Clinical Trials Logo

Biliary Tract Carcinoma clinical trials

View clinical trials related to Biliary Tract Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06463548 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

NCT ID: NCT06430827 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

NCT ID: NCT06168292 Not yet recruiting - Radiotherapy Clinical Trials

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

Start date: December 10, 2023
Phase: N/A
Study type: Interventional

[Study objectives] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.

NCT ID: NCT05822453 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Start date: April 30, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).

NCT ID: NCT05064852 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Start date: September 20, 2021
Phase:
Study type: Observational

This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).